Experts

Scientists Warn to Avoid Treatment by Fake & Untested Stem Cell

By Counsel & Heal Writer | Update Date: Sep 11, 2013 12:04 PM EDT

Experts working on treatments based on the use of stem cells have issued strong warnings about the risks if patients use unproven therapies.

The majority of people resorting to stem cell treatments suffer from incurable degenerative diseases. Often, these patients are ready to do anything for a cure. These fake stem cell treatment manufacturers prey on this obvious desire and extorts thousands in return for bogus therapies.

Dr. Massimo Dominici, president elect of the International Society for Cellular Therapy issued a firm warning at the British Science Festival regarding stem cell research traps set for people with incurable or degenerative diseases.

Dr. Dominici also said patients have to pay hefty amounts of more than 100,000 euros ($132,000) for such “therapies” which include serious brain diseases such as Parkinson’s and Alzheimer’s.

Most of these dodgers usually claim to make of something known as mesenchymal stem cells.

The team of doctors was speaking at a session at the British Science Association’s annual Festival of Science in Newcastle which was part of the science festival.

One company advertises being able to cure more than 100 diseases using transplanted cells. As a matter of surprise, about 100,000 people in the US have already used these untested therapies.

The researchers are gradually getting closer to the treatments in areas related to bones and joints. However, the progress in the field of heart and brain disorders is still slower.

The mesenchymal stem cells works well with certain tissues such as bone, blood and joints but when it comes to nerve and brain tissues, they don't.

The researchers also said that while there were more than 300 clinical trials under way using stem cells, non had reached the point where they were proven to safe as well as effective.

© 2023 Counsel & Heal All rights reserved. Do not reproduce without permission.

Join the Conversation

Real Time Analytics